Form 4: Neurocrine Biosciences Director Kevin Gorman Reports Stock Sale and RSU Vesting

Sentiment:

SEC Form 4


Director Kevin Gorman reports the vesting of restricted stock units and the sale of Neurocrine Biosciences (NBIX) stock under a pre-arranged 10b5-1 trading plan.

Summary

  • Kevin Gorman, a director at Neurocrine Biosciences, reported the vesting of 4,318 restricted stock units (RSUs) on February 8, 2025, which converted into common stock.
  • On February 10, 2025, Gorman sold 2,274 shares of Neurocrine Biosciences common stock at a weighted average price of $118.3673 per share, with prices ranging from $116.06 to $123.53.
  • The sale was executed under a Rule 10b5-1 trading plan adopted on June 10, 2021.
  • Following the reported transactions, Gorman beneficially owns 521,348 shares of Neurocrine Biosciences common stock.

Sentiment

Score: 5

Explanation: This is a routine disclosure of insider trading activity. The use of a 10b5-1 plan suggests the transactions were pre-planned and not based on current inside information. Therefore, the sentiment is neutral.

Industry Context

Form 4 filings are a routine part of insider trading activity and provide transparency into the buying and selling activities of company insiders. The use of 10b5-1 trading plans is a common practice to avoid accusations of insider trading.

Stakeholder Impact

  • The stock sale may have a minor impact on shareholders, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

DateDescription
June 10, 2021Date of adoption of Rule 10b5-1 trading plan.
February 8, 2021Date the RSU was granted to the Reporting Person.
February 8, 2022Date the RSU vested as to 4,317 shares.
February 8, 2023Date the RSU vested as to 4,317 shares.
February 8, 2024Date the RSU vested as to 4,317 shares.
February 8, 2025Date of RSU vesting (4,318 shares).
February 10, 2025Date of stock sale.
February 12, 2025Date of Form 4 filing.

Keywords

Neurocrine Biosciences, NBIX, Kevin Gorman, Form 4, Restricted Stock Units, RSU, Stock Sale, 10b5-1 Trading Plan, Director, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.